FLT3 and acute myeloid leukemia: FLT3-ITD + MV4-11 and MOLM-14 AML cells were treated with either vehicle (DMSO) or quizartinib, crenolanib or gilteritinib at 10 nM for 6 h (h) in SILAC-heavy (Lys8 and Arg10 labeled) medium, followed by protein isolation, tryptic digest, tandem-mass tag (TMT)-based multiplexing, offline fractionation and analysis by LC-MS2 (Fig. 1A).